Quantifying Treatment Resistance in Mixtures of Gastrointestinal Stromal Tumor Cells with BARMIX

Read full text Summarise with VIRAT
Authors: Mohammad Darbalaei, Thomas Mühlenberg, Julia Zummack, Philip Dujardin, Susanne Grünewald, Anna Baginska, Patricia Munteanu, Marina Martinez Cruz, Madeleine Dorsch, Alexander R. Schramm, Sebastian Bauer, Daniel E. Hoffmann
+1 more Barbara M. Grüner
Cited by: 0
References: 39

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT Targeted therapies in gastrointestinal stromal tumors (GIST) often fail due to heterogeneous resistance mutations arising across metastatic sites. Efficient, rational design of mutation-specific therapies requires the ability to quantify treatment resistance across many genotypes in parallel. Here, we present BARcode MIXture analysis (BARMIX), a platform combining multiplexed experiments with DNA-barcoded cancer cell mixtures in vitro and in vivo , and a probabilistic framework for quantitative assessment of genotype-specific treatment resistance. BARMIX efficiently and accurately recapitulated known clinical resistance patterns in GIST and matched resistance measurements from individual cell lines in vitro and in vivo . This experimental-computational approach provides a scalable and broadly applicable strategy for quantifying treatment responses in complex cell populations, enabling systematic preclinical testing of new drugs and combinations to identify mutation-specific therapeutic options for precision oncology in GIST and beyond.

Fields of Study & Subjects

Gastrointestinal Tumor Research and Treatment Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
25 March 2026
Language
EN
Document type
Preprint